WallStreetZenWallStreetZen

NASDAQ: QURE
Uniqure Nv Stock Forecast, Predictions & Price Target

Analyst price target for QURE

Based on 4 analysts offering 12 month price targets for Uniqure Nv.
Min Forecast
$6.00-22.48%
Avg Forecast
$15.75+103.49%
Max Forecast
$25.00+223%

Should I buy or sell QURE stock?

Based on 4 analysts offering ratings for Uniqure Nv.
Buy
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their QURE stock forecasts and price targets.

QURE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-16
lockedlocked$00.00+00.00%2024-07-09
lockedlocked$00.00+00.00%2024-05-08
lockedlocked$00.00+00.00%2024-02-29

1 of 1

Forecast return on equity

Is QURE forecast to generate an efficient return?
Company
22.17%
Industry
71.74%
Market
80.35%
QURE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is QURE forecast to generate an efficient return on assets?
Company
4.22%
Industry
30.97%
QURE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

QURE earnings per share forecast

What is QURE's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$4.40
Avg 2 year Forecast
-$3.48
Avg 3 year Forecast
-$2.11

QURE revenue forecast

What is QURE's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$46.5M+144.44%
Avg 2 year Forecast
$49.9M+162.59%
Avg 3 year Forecast
$121.6M+539.9%
QURE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

QURE revenue growth forecast

How is QURE forecast to perform vs Biotechnology companies and vs the US market?
Company
68.72%
Industry
64.57%
Market
11.26%
QURE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
QURE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

QURE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
QURE$7.74$15.75+103.49%Buy
TRML$14.71$64.67+339.61%Strong Buy
RVNC$3.64$10.00+175.10%Buy
LXEO$11.19$24.25+116.71%Strong Buy
TCRX$6.92$11.40+64.74%Strong Buy

Uniqure Nv Stock Forecast FAQ

Is Uniqure Nv Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: QURE) stock is to Buy QURE stock.

Out of 4 analysts, 1 (25%) are recommending QURE as a Strong Buy, 1 (25%) are recommending QURE as a Buy, 2 (50%) are recommending QURE as a Hold, 0 (0%) are recommending QURE as a Sell, and 0 (0%) are recommending QURE as a Strong Sell.

If you're new to stock investing, here's how to buy Uniqure Nv stock.

What is QURE's earnings growth forecast for 2024-2026?

(NASDAQ: QURE) Uniqure Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.67%.

Uniqure Nv's earnings in 2024 is -$296,869,000.On average, 6 Wall Street analysts forecast QURE's earnings for 2024 to be -$213,457,310, with the lowest QURE earnings forecast at -$257,312,016, and the highest QURE earnings forecast at -$160,213,142. On average, 5 Wall Street analysts forecast QURE's earnings for 2025 to be -$168,757,843, with the lowest QURE earnings forecast at -$234,493,781, and the highest QURE earnings forecast at -$53,404,381.

In 2026, QURE is forecast to generate -$102,439,312 in earnings, with the lowest earnings forecast at -$102,439,312 and the highest earnings forecast at -$102,439,312.

What is QURE's revenue growth forecast for 2024-2026?

(NASDAQ: QURE) Uniqure Nv's forecast annual revenue growth rate of 68.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.26%.

Uniqure Nv's revenue in 2024 is $19,003,000.On average, 4 Wall Street analysts forecast QURE's revenue for 2024 to be $2,255,121,349, with the lowest QURE revenue forecast at $679,692,118, and the highest QURE revenue forecast at $5,602,605,030. On average, 4 Wall Street analysts forecast QURE's revenue for 2025 to be $2,422,616,906, with the lowest QURE revenue forecast at $640,852,568, and the highest QURE revenue forecast at $6,214,327,936.

In 2026, QURE is forecast to generate $5,903,611,539 in revenue, with the lowest revenue forecast at $5,903,611,539 and the highest revenue forecast at $5,903,611,539.

What is QURE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: QURE) forecast ROA is 4.22%, which is lower than the forecast US Biotechnology industry average of 30.97%.

What is QURE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year QURE price target, the average QURE price target is $15.75, with the highest QURE stock price forecast at $25.00 and the lowest QURE stock price forecast at $6.00.

On average, Wall Street analysts predict that Uniqure Nv's share price could reach $15.75 by Jul 16, 2025. The average Uniqure Nv stock price prediction forecasts a potential upside of 103.49% from the current QURE share price of $7.74.

What is QURE's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: QURE) Uniqure Nv's current Earnings Per Share (EPS) is -$6.21. On average, analysts forecast that QURE's EPS will be -$4.40 for 2024, with the lowest EPS forecast at -$5.30, and the highest EPS forecast at -$3.30. On average, analysts forecast that QURE's EPS will be -$3.48 for 2025, with the lowest EPS forecast at -$4.83, and the highest EPS forecast at -$1.10. In 2026, QURE's EPS is forecast to hit -$2.11 (min: -$2.11, max: -$2.11).

What is QURE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: QURE) forecast ROE is 22.17%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.